Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACRIPAB: Bivalirudin vs UFH in High Risk Patients for Bleeding During PCI
NCT00616460Phase 3Completed
- Sponsor
- Emek Medical Center
- Start
- Feb 2008
- Primary completion
- Oct 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bivalirudin in hematologic diseases (2 arms), sponsored by Emek Medical Center. Primary endpoint: Major & minor bleeding and Port of entry related complications at 30 days. Started Feb 2008; status: completed.
02
Drugs
bivalirudin
03
Conditions
hematologic diseases
Beyond the preview
Go deeper on NCT00616460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616460.